

**IN THE CLAIMS:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

1. (Canceled)
2. (Previously presented) An antibody-toxic moiety conjugate comprising (a) an antibody that is specifically reactive with CTLA4 and (b) a toxic moiety.
3. (Previously presented) The antibody-toxic moiety conjugate of claim 2, wherein the antibody is specifically reactive with human CTLA4.
4. (Original) The antibody-toxic moiety conjugate of claim 2, wherein the antibody is a monoclonal antibody.
5. (Original) The antibody-toxic moiety conjugate of claim 2, wherein the antibody binds to a region of the CTLA4 molecule that blocks the binding of CTLA4 to CD80 or CD86.
6. (Original) The antibody-toxic moiety conjugate of claim 2, wherein the antibody binds to a region of the CTLA4 in spatial proximity to the site of CTLA4 binding to a costimulatory molecule.
7. (Previously presented) The antibody-toxic moiety conjugate of claim 2, wherein the substitution of amino acid 83 in the amino acid sequence of human CTLA4 shown in SEQ ID NO: 2 results in reduced binding of the antibody by at least about 80% compared to a human CTLA4 without the substitution of amino acid 83.
8. (Original) The antibody-toxic moiety conjugate of claim 2, wherein the toxic moiety is a carbohydrate.

9. (Original) The antibody-toxic moiety conjugate of claim 8, wherein the carbohydrate is calicheamicin.
10. (Original) The antibody-toxic moiety conjugate of claim 2, wherein the toxic moiety is a naturally occurring bacterial product.
11. (Original) The antibody-toxic moiety conjugate of claim 10, wherein the toxic moiety is selected from the group consisting of ricin A chain and saporin.
12. (Canceled)
13. (Original) The antibody-toxic moiety conjugate of claim 2, wherein the antibody is humanized.
14. (Original) A humanized antibody that is specifically reactive with human CTLA4, wherein the antibody comprises the amino acid sequence shown in SEQ ID NO: 8.
15. (Original) A humanized antibody that is specifically reactive with human CTLA4, wherein the antibody comprises the amino acid sequence shown in SEQ ID NO: 10.
16. (Withdrawn) A method of modulating the immune response comprising contacting a cell with an antibody-toxic moiety conjugate of claim 2.
17. (Withdrawn) The method of claim 16, wherein the antibody-toxic moiety conjugate is administered to a subject and the step of contacting is performed *in vivo*.
18. (Withdrawn) The method of claim 17, wherein the subject is suffering from a disorder or condition that would benefit from downmodulation of an ongoing immune response wherein the disorder or condition is selected from the group consisting of: an

autoimmune disorder, an immune response to a graft, an allergic response, an immune response to a therapeutic protein.

19. (Withdrawn) The method of claim 16, wherein the step of contacting is performed *in vitro*.

20. (Withdrawn) A method of modulating the immune response comprising contacting a cell within an antibody specifically reactive with CTLA4, wherein the antibody is produced by a hybridoma selected from the group consisting of: ATCC Accession No. \_\_\_\_ (hybridoma \_\_\_\_), ATCC Accession No. \_\_\_\_ (hybridoma \_\_\_\_), ATCC Accession No. \_\_\_\_ (hybridoma \_\_\_\_), ATCC Accession No. \_\_\_\_ (hybridoma \_\_\_\_), ATCC Accession No. \_\_\_\_ (hybridoma \_\_\_\_), ATCC Accession No. \_\_\_\_ (hybridoma \_\_\_\_), ATCC Accession No. \_\_\_\_ (hybridoma \_\_\_\_), ATCC Accession No. \_\_\_\_ (hybridoma \_\_\_\_), ATCC Accession No. \_\_\_\_ (hybridoma \_\_\_\_).

21. (Withdrawn) A method of modulating the immune response comprising contacting a cell with an antibody specifically reactive with human CLTA4, wherein the antibody comprises an amino acid sequence shown in SEQ ID NO:8.

22. (Withdrawn) A method of modulating the immune response comprising contacting a cell with an antibody specifically reactive with human CLTA4, wherein the antibody comprises an amino acid sequence shown in SEQ ID NO: 10.

23. (Withdrawn) A method of downmodulating the immune response comprising contacting a cell with an antibody-toxic moiety conjugate, wherein the antibody specifically recognizes CTLA4.

24. (New) The antibody-toxic moiety conjugate of claim 2, wherein the toxic moiety is a chemotherapeutic agent.